Antitumoral Cascade-Targeting Ligand for IL-6 Receptor-Mediated Gene Delivery to Glioma

Area of Science:

• Biomedical Engineering
• Neuroscience
• Oncology

Background:

• Glioma treatment faces challenges due to the blood-brain barrier (BBB) and difficulty distinguishing tumor from healthy cells.
• Current drug delivery systems struggle with efficient BBB penetration and targeted glioma delivery.
• Novel strategies are needed to overcome these barriers for effective glioma therapy.

Purpose of the Study:

• To develop a novel gene delivery system for glioma therapy using a dual-targeting peptide.
• To evaluate the efficacy of the I₆P₇ peptide in crossing the BBB and targeting glioma cells.
• To assess the therapeutic potential of the I₆P₇-modified system in vivo.

Main Methods:

• A nonviral gene delivery system (I₆P₇-Stp-His/DNA) was constructed using an interleukin-6 receptor binding I₆P₇ peptide.
• The system's ability to cross the BBB and target glioma cells was tested in vitro (transwell bEnd.3 cell model) and in vivo (glioma-bearing mice).
• Gene expression, cellular uptake, and therapeutic efficacy (survival time) were evaluated in U87 glioma cells and orthotopic glioma models.

Main Results:

• I₆P₇-Stp-His/DNA nanoparticles showed enhanced gene expression in glioma cells compared to healthy cells.
• The nanoparticles demonstrated deeper penetration into glioma spheroids and successful BBB transport in vitro and in vivo.
• Intravenous administration of I₆P₇-Stp-His/pING4 significantly prolonged survival in orthotopic glioma-bearing mice.

Conclusions:

• The I₆P₇ peptide functions as a robust cascade-targeting ligand, facilitating BBB crossing and glioma targeting.
• I₆P₇-modified nanoparticles hold promise as an efficient platform for glioma therapy.
• This novel approach offers a potential strategy to overcome key challenges in glioma treatment.